Tag: HEPA Stock


Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Announces that they Achieved All the Primary Endpoints in their ‘Ambition’ Nash Phase 2a Trial

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) is a clinical-stage biopharma company that focuses on developing therapeutic medications that can help treat liver diseases caused by non-alcoholic steatohepatitis. The company recently announced that they received positive topline results from the ‘Ambition’ NASH trial. In addition, they said that they met all the primary […]